# **Product** Data Sheet

## **ZK53**

Cat. No.: HY-149677 Molecular Formula:  $C_{19}H_{20}BrF_{2}N_{3}O$ 

Molecular Weight: 424.28

Mitochondrial Metabolism Target: Pathway: Metabolic Enzyme/Protease Storage:

Powder -20°C 3 years 4°C 2 years

In solvent -80°C 6 months

> -20°C 1 month

#### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 200 mg/mL (471.39 mM; ultrasonic and warming and heat to 80°C)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.3569 mL	11.7847 mL	23.5693 mL
	5 mM	0.4714 mL	2.3569 mL	4.7139 mL
	10 mM	0.2357 mL	1.1785 mL	2.3569 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 5 mg/mL (11.78 mM); Clear solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 5 mg/mL (11.78 mM); Clear solution; Need ultrasonic

### **BIOLOGICAL ACTIVITY**

Description

ZK53 is a selective activator of mitochondrial caseinolytic protease P (HsClpP) (EC $_{50}$ : 1.37? $\mu$ M for  $\alpha$ -casein hydrolysis by HsClpP). ZK53 is is inactive toward bacterial ClpP proteins. ZK53 induces apoptosis in H1703, H520 and SK-MES-1 cells. ZK53 induces dysregulation of mitochondrial functions in lung squamous cell carcinoma (LUSC) cells. ZK53 inhibits tumor growth in H1703 xenograft mouse model<sup>[1]</sup>.

#### **REFERENCES**

[1]. Zhou LL, et al. Selective activator of human ClpP triggers cell cycle arrest to inhibit lung squamous cell carcinoma. Nat Commun. 2023 Nov 3;14(1):7069.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com